Acute bacterial prostatitis and abscess formation

Lee, Dong Sup; Choe, Hyun-Sop; Kim, Hee Youn; Kim, Sun Wook; Bae, Sang Rak; Yoon, Byung Il; Lee, Seung-Ju

doi:10.1186/s12894-016-0153-7

BMC Urology

Table 1 Demographic characteristics in 142 acute febrile prostatic infections

From: Acute bacterial prostatitis and abscess formation

	With abscess (n = 31)	Without abscess (n = 111)	Statistical results
Underlying factors
Age (years)†	62.23 ± 14.60	63.99 ± 14.27	0.546, 2.913, −7.524 ~ 3.994
BMI (Kg/m²)†	23.93 ± 4.04	24.05 ± 3.79	0.887, 0.827, −1.756 ~ 1.521
PSA (ng/ml)†	15.95 ± 11.46	20.76 ± 19.17	0.200, 3.730, −12.181 ~ 2.571
Prostate size (cc)†	47.73 ± 19.25	40.80 ± 17.53	0.063, 3.694, −0.377 ~ 14.242
Abscess size (mm)	22.03 ± 11.69	NA
Abscess size (mm)	<10 mm: 4; 10 ~ 20 mm: 12; 20 ~ 30 mm: 8; >30 mm: 7
Other abscess foci	4; 2 liver abscesses, 1 renal abscess, 1 buttock abscess	2; 1 liver abscess, 1 renal abscess	NA
Symptom duration†	7.81 ± 5.42	3.04 ± 2.57	<0.001, 0.691, 3.404 ~ 6.136
Underlying diseases
Diabetes mellitus‡	16/31	32/111	0.030, 2.633, 1.165 ~ 5.951
Hypertension‡	11/31	49/111	0.418, 0.696, 0.305 ~ 1.589
Heart disease‡	4/31	23/104	0.316, 0.522, 0.166 ~ 1.644
Neurological deficit‡	10/31	31/111	0.658, 1.229, 0.520 ~ 2.903
Chronic kidney disease*	4/31	16/111	1.000, 0.880, 0.271 ~ 2.851
Chronic lung disease*	2/31	11/111	0.734, 0.627, 0.131 ~ 2.991
Liver cirrhosis*	7/31	15/111	0.261, 1.867, 0.685 ~ 5.087
Previous hospitalizations‡	8/31	16/111	0.174, 2.065, 0.788 ~ 5.411
Urological procedures*	3/31 3 cystoscopy	10/111 4 cystoscopy 4 prostate biopsy 2 urodynamic study	1.000, 1.082, 0.279 ~ 4.201 0.176, 2.866, 0.606 ~ 13.553 NA NA
Long term catheterization*	2/31	12/111	0.735, 0.569, 0.120 ~ 2.689
Recent catheterization*	5/31	8/111	0.158, 2.476, 0.748 ~ 8.198
Voiding disturbance (Qmax < 5 or PVR > 100)‡	15/31	15/111	<0.001, 6.000, 2.464 ~ 14.612
Treatment outcomes
Septic shock*	3/31	3/111	0.118, 3.857, 0.738 ~ 20.152
Death	1/31	1/111	0.390, 3.667, 0.223 ~ 60.360
Recurrence	1/31	3/111	1.000, 1.189, 0.119 ~ 11.848
Treatment duration†	40.96 ± 10.61	26.98 ± 9.43	<0.001, 2.111, 9.802 ~ 18.158
With TUR-P (n = 13)^a	32.31 ± 9.34		0.001††
Without TUR-P (n = 13)^b	40.85 ± 7.94		0.001††
Admission duration†	12.38 ± 6.59	6.69 ± 2.92	<0.001, 1.321, 2.978 ~ 8.403
With TUR-P (n = 13)^a	10.23 ± 2.55		0.650††
Without TUR-P (n = 13)^b	11.08 ± 9.32		0.650††
Follow-up duration†	216.0 ± 69.92	202.11 ± 59.01	0.302, 13.391, −12.602 ~ 40.378

†: These continuous values are expressed as means ± standard deviations and student t-tests were performed (statistical data include p-values, standard errors and 95 % confidence intervals, respectively)
‡,*: Statistical evaluation for the nominal parameters was performed using the Chi-squared test‡ or Fisher’s exact test* (statistical data include p-values, odds ratios and 95 % confidence intervals, respectively.)
††: p-values between ‘a’ and ‘b’ were evaluated using the Mann–Whitney U test. Note that all cases (n = 13) treated by TUR-P had abscesses >20 mm in size
Among the 142 cases, 6 cases with metastatic abscesses (1 patient underwent TUR-P) and 2 fatal cases were excluded when comparing the treatment duration, admission duration and follow-up duration
Abbreviations: BMI body mass index; PSA prostate specific antigen; Qmax (ml/sec) maximum urinary flow rate; PVR (ml) post-void residual; TUR-P transurethral resection of prostate

Back to article page

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com